The accord adds to the breadth of Kerry’s probiotic abilities. Kerry first acquired Ganeden, based in Cleveland, OH and her BC-30 Coagulating bacilliIngredient in 2017. The company followed this up with the acquisition of Canadian probiotic manufacturer Bio-K + International in 2020. And he went on to build a potent probiotic portfolio with the Acquisition of the Spanish probiotic developer Biosearch Lifeearlier this year.
The ingredient MB40 is a proprietary strain of Bacillus subtilis (strain # ATCC122264), which, like the ingredient BC-30, is a spore-forming organism, which is likely to provide some formulation flexibility over standard probiotics.
A parallel design study carried out with the ingredient in 2019has been shown to reduce bloating compared to placebo for some groups. According to Kerry’s analysis, the study “Has shown promising results for the probiotic strain to support gastrointestinal health. “
“Given the impressive performance of strain MB40 and its potential to have a significant impact on the dietary supplement, functional food and drink, and companion animal industries, we have decided to work with a partner who will help make evolve MB40 globally. “said Chris Schuler, CEO of BIO-CAT.
“Kerry’s expertise, commitment to developing a leading probiotic platform, access to global resources, and plans to further scientifically support MB40 make her an ideal partner,” he added.
As part of the deal, Kerry will take over branding for MB40. A “refresh” of the brand will be undertaken, which should be completed in several months. Next, the brand will be offered at Kerry’s 150 outlets in 31 countries around the world.
“We are delighted to partner with Bio-Cat to further develop and commercialize this unique and very stable strain of Bacillus, which will complement our growing portfolio of science-backed branded ingredients in our ProActive Health portfolio,”said John Quilter, vice president and general manager of Kerry’s ProActive Health business unit.
Quilter took over the management of Ganeden after the acquisition of Kerry. Previously, he managed the immune support ingredients business Wellmune, which Kerry acquired from Biothera in 2015.
Focus on functional foods, drinks
The MB40 commercialization agreement is in line with Kerry’s strategic focus on functional foods and beverages, rather than focusing on the dietary supplement markets.
“Today, nearly 40% of consumers globally actively seek out functional foods and beverages to meet their specific health needs, which means they are twice as likely to seek out a food option and of drinks than a nutritional supplement. And we are seeing this campaign for functional foods in consumers at all stages of life and all demographics. And these function claims are also a key driver of growth in consumer food and drink products, ” Kerry CEO Edmond Scanlon said on a recent earnings conference call with equity analysts. A transcript of the call has been posted on seekalpha.com.
Kerry recorded $ 8.6 billion (€ 7 billion) in revenue in its fiscal 2020, down 3.3% year-over-year.
Editor’s Note: This article was originally published with an image illustrating mergers and acquisitions. However, the agreement between Kerry Group and BIO-CAT Microbials, LLC is a license agreement / supplierand not an acquisition. We apologize for any confusion.